ADIM
NEO icon

Alpha DNA Investment Management’s NeoGenomics NEO Stock Holding History

Alpha DNA Investment Management’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-26,301
Closed -$426K – 228
2023
Q4 		$426K Sell
26,301
-13,147
-33% -$215K 0.17% 149
2023
Q3 		$485K Sell
39,448
-5,017
-11% -$74.6K 0.2% 142
2023
Q2 		$715K Buy
+44,465
New +$733K 0.24% 132

Other funds holding NEO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Alpha DNA Investment Management's NEO Position: Q1 2024 in Review

Alpha DNA Investment Management sold out of NeoGenomics (NEO) in Q1 2024, closing a stake of 26,301 shares — an estimated $426K sold.

Alpha DNA Investment Management first reported a position in NEO in Q2 2023 and held it in 3 quarters. The position peaked at $715K in Q2 2023. 263 funds tracked by Wall St. Rank hold NEO as of Q1 2024.

  • Alpha DNA Investment Management reported no remaining NeoGenomics position as of Q1 2024 after selling out during the quarter.
  • Alpha DNA Investment Management sold 26,301 NeoGenomics shares in Q1 2024, an estimated $426K.
  • Alpha DNA Investment Management first reported a position in NeoGenomics in Q2 2023 and held it in 3 quarters.
  • Alpha DNA Investment Management's NeoGenomics position peaked at $715K in Q2 2023.
  • 263 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2024.

Based on Alpha DNA Investment Management's 13F filing for Q1 2024, filed 15 May 2024.